Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients
[Clinical Medicine Insights: Oncology] Cancer cachexia affects many advanced non-small-cell lung cancer (NSCLC) patients.
[Clinical Medicine Insights: Oncology] Cancer cachexia affects many advanced non-small-cell lung cancer (NSCLC) patients.
[OncoTargets and Therapy] According to the hypothesis of internal mammary sentinel lymph node, lymphatic drainage pattern, a modified radiotracer injection technique was established.
[Clinical Medicine Insights: Oncology] Although myelosuppression is the most adverse event of this therapy, gemcitabine might induce severe pulmonary toxicities.
[Blood and Lymphatic Cancer Targets and Therapy] Imatinib was the first tyrosine kinase inhibitor (TKI), successfully used in a clinical setting.
[Clinical Medicine Insights: Oncology] Given the absence of association between multiple sclerosis, diffuse large B-cell lymphoma, causal association with natalizumab cannot be excluded.
[Cancer Control] Molecular testing is entrenched in the workup and management of hematological malignancies.
[Translational Lung Cancer Research] This research investigates the prevalence and clinicopathological features of BRAF mutations in non-small cell lung cancer (NSCLC) cases submitted for routine mutation testing.
[Biomarkers in Cancer] Cluster of differentiation 151 (CD151) functions at various stages of cancer, including metastatic cascade and primary tumor growth, reinforcing the importance of CD151 as a target in oncology.
[Breast Cancer: Targets and Therapy] This review focuses on the role of the WASP/WAVE family in breast cancer cell invasion and migration.
[Clinical Oncology in Adolescents and Young Adults] Integration of palliative care at the time of diagnosis enables a supportive partnership with the medical team.